Sylvie Guichard Selected Research

(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanol

2/2013	Combined inhibition of mTORC1 and mTORC2 signaling pathways is a promising therapeutic option in inhibiting pheochromocytoma tumor growth: in vitro and in vivo studies in female athymic nude mice.
6/2011	mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment.
5/2010	Simultaneous inhibition of mTORC1 and mTORC2 by mTOR kinase inhibitor AZD8055 induces autophagy and cell death in cancer cells.
1/2010	AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sylvie Guichard Research Topics

Disease

12	Neoplasms (Cancer) 01/2020 - 12/2005
2	Sickle Cell Anemia (Hemoglobin S Disease) 01/2022 - 11/2021
2	Hypertension (High Blood Pressure) 01/2020 - 10/2018
2	Gastrointestinal Stromal Tumors (Gastrointestinal Stromal Tumor) 01/2020 - 10/2018
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 07/2014 - 03/2013
2	Colonic Neoplasms (Colon Cancer) 07/2009 - 10/2002
2	Colorectal Neoplasms (Colorectal Cancer) 05/2007 - 07/2002
1	Hemoglobinopathies 01/2022
1	Sarcoma (Soft Tissue Sarcoma) 01/2020
1	Disease Progression 01/2020
1	Ataxia Telangiectasia (Louis Bar Syndrome) 11/2018
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 02/2016
1	Breast Neoplasms (Breast Cancer) 06/2013
1	Leukemia 03/2013
1	Pheochromocytoma 02/2013
1	Renal Cell Carcinoma (Grawitz Tumor) 06/2011
1	Adenoma (Adenomas) 05/2007
1	Ovarian Neoplasms (Ovarian Cancer) 12/2005

Drug/Important Bio-Agent (IBA)

7	Phosphotransferases (Kinase)IBA 11/2018 - 05/2010
4	(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA 02/2013 - 01/2010
3	Mechanistic Target of Rapamycin Complex 1IBA 02/2013 - 01/2010
2	Sickle HemoglobinIBA 01/2022 - 11/2021
2	AZD3229IBA 01/2020 - 10/2018
2	Mechanistic Target of Rapamycin Complex 2IBA 02/2013 - 05/2010
2	Pharmaceutical PreparationsIBA 02/2013 - 06/2011
2	Adenosine Triphosphate (ATP)IBA 02/2013 - 06/2011
2	Sirolimus (Rapamycin)FDA Link 06/2011 - 01/2010
2	Irinotecan (Camptosar)FDA LinkGeneric 10/2002 - 07/2002
2	Topoisomerase I InhibitorsIBA 10/2002 - 07/2002
1	Pyruvate KinaseIBA 01/2022
1	Oxygen (Dioxygen)IBA 01/2022
1	Sunitinib (Sutent)FDA Link 01/2020
1	regorafenibIBA 01/2020
1	Platelet-Derived Growth FactorIBA 01/2020
1	Vascular Endothelial Growth Factor Receptor-2 (Vascular Endothelial Growth Factor Receptor 2)IBA 01/2020
1	Antineoplastic Agents (Antineoplastics)IBA 11/2018
1	ceralasertibIBA 11/2018
1	DNA (Deoxyribonucleic Acid)IBA 11/2018
1	acetamideIBA 10/2018
1	quinolineIBA 10/2018
1	Tyrosine Kinase InhibitorsIBA 10/2018
1	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 10/2018
1	Tyrosine (L-Tyrosine)FDA Link 02/2016
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 07/2014
1	Dyrk KinasesIBA 01/2014
1	MK 2206IBA 06/2013
1	Protein Kinases (Protein Kinase)IBA 06/2013
1	capivasertibIBA 06/2013
1	p21-Activated KinasesIBA 03/2013
1	Cyclin-Dependent Kinases (cdk Proteins)IBA 03/2013
1	Casein Kinases (Casein Kinase)IBA 03/2013
1	TOR Serine-Threonine KinasesIBA 02/2013
1	Taxoids (Taxanes)IBA 07/2009
1	NF-kappa B (NF-kB)IBA 05/2007
1	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 05/2007
1	NF-KappaB Inhibitor alphaIBA 05/2007
1	hexamethylbenzeneIBA 12/2005
1	LigandsIBA 12/2005
1	AzidesIBA 12/2005
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 10/2002
1	PlatinumIBA 10/2002

Therapy/Procedure

2	Therapeutics 10/2018 - 05/2007
1	Immunotherapy 06/2011